SAG
NGNE icon

SageView Advisory Group’s Neurogene NGNE Stock Holding History

SageView Advisory Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$927 Buy
+45
New +$1.12K ﹤0.01% 2373

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SageView Advisory Group's NGNE Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Neurogene (NGNE) in Q4 2025: 45 shares worth $927. The stake represents ﹤0.01% of the portfolio and ranks #2373 among its holdings.

93 funds tracked by Wall St. Rank hold NGNE as of Q4 2025.

  • SageView Advisory Group held 45 shares of Neurogene worth $927 as of Q4 2025.
  • Neurogene was a new SageView Advisory Group position in Q4 2025.
  • Neurogene made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2373 holding.
  • 93 funds tracked by Wall St. Rank held Neurogene as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.